Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Gris-Oliver, A; Palafox, M; Monserrat, L; Braso-Maristany, F; Odena, A; Sanchez-Guixe, M; Ibrahim, YH; Villacampa, G; Grueso, J; Pars, M; Guzman, M; Rodriguez, O; Bruna, A; Hirst, CS; Barnicle, A; de Bruin, EC; Reddy, A; Schiavon, G; Arribas, J; Mills, GB; Caldas, C; Dienstmann, R; Prat, A; Nuciforo, P; Razavi, P; Scaltriti, M; Turner, NC; Saura, C; Davies, BR; Oliveira, M; Serra, V

Serra, V (corresponding author), Vall dHebron Inst Oncol VHIO, Carrer Natzaret 115-117, Barcelona 08035, Spain.

CLINICAL CANCER RESEARCH, 2020; 26 (14): 3720

Abstract

Purpose: AZD5363/capivasertib is a pan-AKT catalytic inhibitor with promising activity in combination with paclitaxel in triple-negative metastatic br......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索